Even with these limitations, we found specific biomarker signatures for MSUD patients and neuropsychiatric dysfunctions in IEMs patients, that pointed to CACNA2D2, THBS1,3, MECP2, and LIN28A as new potential phenotype modifiers, after further investigation and verification with larger samples. The gene discussed is LIN28A; the disease is maple syrup urine disease.